Status:
COMPLETED
MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Pregnancy
Primiparity
Eligibility:
FEMALE
18-50 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether close monitoring of patients with a high sFlt1 plasma level between 25 and 28 weeks of gestation (i.e. at high risk of subsequent preeclampsia) improv...
Detailed Description
We will measure plasmatic sFlt-1 level between 25 and 28 weeks of gestation and flow velocity of uterine arteries by Doppler (22 - 26 weeks of gestation) in primipara. Patients will be stratified acco...
Eligibility Criteria
Inclusion
- Pregnant womenAge ≥ 18 years
- Followed in our center before the 28th week of gestation
- Under social security coverage
- Signed informed consent
Exclusion
- Age \< 18 years
- Followed in our center after the 28th week of gestation
- No social security coverage
- Refusal to be included
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
1040 Patients enrolled
Trial Details
Trial ID
NCT00763672
Start Date
November 1 2008
End Date
June 1 2011
Last Update
March 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gynecology Obstetrics and Reproductive Medicine, Hôpital Tenon, AP-HP, UPMC
Paris, France, 75020